Schonfeld Strategic Advisors
AXSM icon

Schonfeld Strategic Advisors’s Axsome Therapeutics AXSM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-50,000
Closed -$1.65M – 2138
2021
Q3 		$1.65M Buy
+50,000
New +$1.95M 0.02% 780

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Deep Track Capital
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Schonfeld Strategic Advisors's AXSM Position: Q2 2026 in Review

Schonfeld Strategic Advisors opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 35,608 shares worth $8.72M. The stake represents 0.03% of the portfolio and ranks #458 among its holdings. This is a return to the name: Schonfeld Strategic Advisors previously reported a position in AXSM as recently as Q2 2025.

Schonfeld Strategic Advisors first reported a position in AXSM in Q1 2019 and has held it in 22 quarters since. The position peaked at $15.7M in Q2 2019. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Schonfeld Strategic Advisors held 35,608 shares of Axsome Therapeutics worth $8.72M as of Q2 2026.
  • Axsome Therapeutics was a new Schonfeld Strategic Advisors position in Q2 2026.
  • Axsome Therapeutics made up 0.03% of Schonfeld Strategic Advisors's portfolio in Q2 2026, its #458 holding.
  • Schonfeld Strategic Advisors first reported a position in Axsome Therapeutics in Q1 2019 and has held it in 22 quarters since.
  • Schonfeld Strategic Advisors's Axsome Therapeutics position peaked at $15.7M in Q2 2019.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.